Prevalence of Asymptomatic Hyperuricemia and Associated Factors in Patients With Type 2 Diabetes Mellitus: A Cross-sectional Study in Southern Vietnam
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background Asymptomatic hyperuricemia is a common yet frequently overlooked condition in the management of patients with type 2 diabetes mellitus (T2DM), despite its potential association with cardiovascular events. This study aimed to determine the prevalence and associated factors of asymptomatic hyperuricemia among patients with T2DM. Methods A cross-sectional study was conducted on 235 patients with T2DM at a tertiary hospital. Demographic, clinical, laboratory, and medication data were collected. Asymptomatic hyperuricemia was defined as a serum uric acid level ≥ 420 µmol/L in men or ≥ 360 µmol/L in women, in the absence of clinical symptoms of gout. Hyperuricemia was classified by severity, and logistic regression analysis was used to identify associated factors. Results The prevalence of asymptomatic hyperuricemia was 31.1%, with 25.9% categorized as mild and 5.1% as severe. Independent associated factors included body mass index (adjusted OR: 1.18; 95% CI: 1.01–1.36; p = 0.032), alcohol consumption (adjusted OR: 6.05; 95% CI: 1.79–20.41; p = 0.004), and lower estimated glomerular filtration rate (eGFR) (adjusted OR: 0.96; 95% CI: 0.93–0.99; p = 0.012). Subgroup analyses based on sex, renal function, and alcohol use demonstrated that these factors remained significant. The area under the receiver operating characteristic (ROC) curve for the predictive model was 0.869 (95% CI: 0.818–0.920). Conclusions Asymptomatic hyperuricemia is prevalent in patients with T2DM (31.1%) and is associated with modifiable risk factors such as overweight, alcohol consumption, and chronic kidney disease. Routine screening for serum uric acid should be considered as part of the comprehensive cardiovascular–renal–metabolic risk assessment in patients with diabetes.